EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , 

 ISSN 2394- 3211

Impact Factor: 4.161

 ICV - 45.77

Abstract

SAFETY AND EFFICACY OF DEWDERM AD CREAM IN PATIENTS WITH ATOPIC DERMATITIS: A 60-DAYS, PROSPECTIVE, OPEN-LABEL CLINICAL STUDY.

Dr. Muhammed Majeed, Dr. Raju Rhee, Smitha Thazhathidath, Mahesh Paschapur, Nataraj Eramuddappa, Kiran Kumar Vuppala*

ABSTRACT

Objective: To evaluate the safety and efficacy of a formulation, Dewderm AD cream, in patients with mild-to-moderate atopic dermatitis (AD). Methods: Thirty six subjects with mild-to-moderate AD aged between 5–55 years were enrolled in the study. All 36 patients were instructed to apply Dewderm AD cream twice daily on the affected area for 60 days irrespective of their visits to the clinic. Subjects underwent evaluation of efficacy parameters, such as effect of skin surface hydration and assessment of disease severity, quality of life at the end of the treatment, and photographs were taken before and after the treatment (i.e. on day 60) to assess clinical improvement of the severity of AD. Results: Treatment with Dewderm AD cream showed statistically significant improvement in all the efficacy parameters at different time points from baseline to end of the study. A statistically significant (p < 0.05) increase in mean skin surface hydration with 54.86% improvement at visit 5 was observed when compared to baseline. SCORAD score showed 80.22% reduction in the severity of skin lesions by the end of the treatment period suggesting progressive improvement in the disease severity. Similarly, the investigator‟s global assessment (IGA) scale also showed a statistically significant reduction of 67.01% from baseline 2.69 ± 0.47 to 0.88 ± 0.40 at the end of the study (p < 0.05). The DLQI score also demonstrated a statistically significant decrease (p < 0.05) from baseline to end of the study. Additionally, photograph comparing before and after treatment showed gradual clinical improvement in severity of AD of the affected area at the end of the study in subjects who had skin lesions at baseline. No adverse events were reported during the study. Conclusion: Dewderm AD cream was very effective in treating mild-to-moderate AD by significantly reducing the disease severity without any side effects. Hence, the formulation is an effective and safe treatment option in patients with mild-to-moderate AD.

Keywords: Atopic dermatitis, Investigator?s Global Assessment, Quality of Life.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • EJPMR OCTOBER ISSUE PUBLISHED

    OCTOBER 2017 Issue has been successfully launched on 1 October 2017

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 October 2017 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from 3.628 to 4.161 due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 45.77, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process)